Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – ...
Beyond traditional clinicopathologic factors, genomic insights from the GPS Mdx test can help distinguish patients with favorable vs unfavorable prostate tumor biology, even among clinically ...
A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable improvement in urinary symptoms and flow rate, according to data from three ...
A new study indicated that the Bellmunt Risk Score can help stratify survival outcomes in patients with metastatic castration-resistant prostate cancer. Using data from more than 1700 patients across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results